Rapport Therapeutics, Inc. (Nasdaq: RAPP) is a clinical-stage biotechnology company that regularly issues news about its precision neuroscience programs for neurological and psychiatric disorders. The company’s updates often center on RAP-219, a potential first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator being evaluated in drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain.
News for RAPP commonly includes clinical trial milestones, such as Phase 2a results in focal onset seizures, post hoc analyses presented at scientific meetings, and plans for registrational Phase 3 programs. Rapport has reported statistically significant reductions in long episodes and clinical seizures in its Phase 2a FOS trial, along with additional analyses on early onset of action, consistency of response, and improvements in seizure severity measures.
Investors and clinicians following Rapport can also expect announcements about regulatory interactions with the U.S. Food and Drug Administration, including end-of-Phase 2 meetings, clinical hold updates, and investigational new drug (IND)-enabling activities. The company provides updates on its long-acting injectable formulation of RAP-219, its α6β4 nicotinic acetylcholine receptor program for chronic pain and migraine, and other discovery and preclinical efforts in hearing and vestibular disorders.
RAPP news flow further covers financial and corporate developments, such as public offerings of common stock under an effective shelf registration statement, quarterly financial results, and participation in healthcare and investor conferences. For readers tracking Rapport Therapeutics, this news stream offers insight into the progress of its RAP technology platform, the evolution of its epilepsy portfolio, and the status of its broader pipeline in neurology and psychiatry.
Rapport Therapeutics (Nasdaq: RAPP) announced accelerated initiation of its RAP-219 Phase 3 focal onset seizures (FOS) program, expected to begin in Q2 2026 after an End-of-Phase-2 meeting with the FDA that allows registrational trials. The company is expanding its epilepsy portfolio into primary generalized tonic-clonic seizures (PGTCS) with a planned Phase 3 start in H1 2027.
Other pipeline updates: an open-label long-term safety trial for RAP-219 is enrolling (initial data expected H2 2026), Phase 2 bipolar mania trial remains enrolling with topline expected H1 2027, IND-enabling for a long-acting injectable starts Q1 2026, and the FDA lifted the clinical hold on the RAP-219 DPNP IND while the company defers further DPNP investment to prioritize an α6β4 pain program. Cash was $513.0M at quarter end, which management says funds operations into H2 2029.
Rapport Therapeutics (Nasdaq: RAPP) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 11:15 a.m. PST / 2:15 p.m. EST. A live and archived webcast of the presentation will be available in the Investors section of the company website.
Investors can access the webcast at https://investors.rapportrx.com for live viewing and later replay.
Rapport Therapeutics (Nasdaq: RAPP) reported new post-hoc and clinical data for RAP-219 in drug-resistant focal onset seizures presented at AES on Dec 5, 2025. The Phase 2a trial (n=30) met its primary endpoint with a statistically significant reduction in long episodes and showed a 77.8% median reduction in clinical seizures versus baseline and 24% seizure freedom during the 8-week treatment (p=0.01; seizure-free p<0.0001). RAP-219 showed early onset and consistent median efficacy across weeks 1-4 and 5-8, benefit across baseline severity groups, clinically meaningful improvements on seizure severity domains, generally favorable tolerability, and a 10% discontinuation rate. The company plans an end-of-Phase 2 FDA meeting this quarter and expects to start two pivotal Phase 3 trials in Q3 2026.
Rapport Therapeutics (Nasdaq: RAPP) will present new Phase 2a data for RAP-219 in focal onset seizures at the 2025 American Epilepsy Society Annual Meeting, Dec 5–9 in Atlanta.
Presentations include topline efficacy and safety, analyses of first-month effect, consistency of efficacy over treatment, impact of baseline disease severity, and effect on seizure severity. Posters and a Scientific Exhibit Room (GWCC B303) are scheduled for Dec 7–8; materials will be posted to the company Publications page after the conference.
Rapport Therapeutics (Nasdaq: RAPP) reported Q3 2025 results and a business update on Nov 6, 2025. Key clinical highlights include positive Phase 2a topline data for RAP-219 in drug-resistant focal onset seizures: 77.8% median reduction in clinical seizures, 72% of patients with ≥50% reduction, and 24% seizure freedom over an 8-week treatment (p-values ≤0.01). The trial met its primary electrographic endpoint (85.2% ≥30% reduction in long episodes; p<0.0001).
Corporate and financials: completed a public offering raising net proceeds of $269.4M, ended Q3 with $513.0M in cash and equivalents, and expects funding into H2 2029. Two Phase 3 trials planned to start Q3 2026; bipolar Phase 2 topline expected H1 2027.
Rapport Therapeutics (Nasdaq: RAPP) announced management will participate in two upcoming investor conferences in November 2025: a fireside chat at the Stifel 2025 Healthcare Conference in New York on Nov 13, 2025, 1:20–1:50pm ET, and a fireside chat at the Jefferies Global Healthcare Conference in London on Nov 17, 2025, 1:00–1:25pm GMT (8:00–8:25am ET).
Interested parties can access live and archived webcasts via the company’s Investors website at https://investors.rapportrx.com.
Rapport Therapeutics (NASDAQ:RAPP), a clinical-stage biotech company focused on developing small molecule precision medicines for neurological and psychiatric disorders, has announced its participation in an upcoming investor conference.
Management will participate in a fireside chat at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17, 2025, at 11:20 am ET. The virtual event will be accessible via webcast on the company's investor relations website.
Rapport Therapeutics (NASDAQ:RAPP), a clinical-stage biotech company focusing on neurological and psychiatric disorder treatments, has announced the pricing of its public offering. The company is offering 9,615,385 shares at $26.00 per share, with an additional 30-day option for underwriters to purchase up to 1,442,307 shares.
The offering is expected to generate gross proceeds of approximately $250.0 million before deductions and is anticipated to close around September 11, 2025. Goldman Sachs, Jefferies, TD Cowen, and Stifel are serving as joint book-running managers for this offering, which is being conducted under an effective shelf registration statement previously filed with the SEC.
[ "Expected to raise substantial capital of $250.0 million in gross proceeds", "Strong underwriting support from major investment banks", "Additional flexibility with 30-day option for underwriters to purchase more shares" ]Rapport Therapeutics (NASDAQ:RAPP), a clinical-stage biotech company focused on neurological and psychiatric disorder treatments, has announced a proposed public offering of $250.0 million of common stock. The company will grant underwriters a 30-day option to purchase up to an additional $37.5 million of shares.
The offering will be managed by joint book-runners Goldman Sachs, Jefferies, TD Cowen, and Stifel. The securities will be offered through an effective shelf registration statement previously filed with the SEC. The completion of the offering is subject to market conditions, with no guarantee of final terms or completion.
Rapport Therapeutics (NASDAQ: RAPP) announced positive topline results from its Phase 2a clinical trial of RAP-219 in patients with drug-resistant focal onset seizures. The trial met its primary endpoint with 85.2% of patients achieving ≥30% reduction in long episodes from baseline (p<0.0001). Notably, patients demonstrated a 77.8% median reduction in clinical seizure frequency (p=0.01), with 24% achieving complete seizure freedom during the 8-week treatment period.
The drug was generally well-tolerated, with mostly mild adverse events and no serious adverse events reported. Based on these promising results, Rapport plans to advance RAP-219 into two Phase 3 pivotal trials in Q3 2026, following an FDA end-of-Phase 2 meeting in Q4 2025. The company is also developing a long-acting injectable formulation to improve patient adherence.